ИСТИНА

Chemotherapy, one of the main methods of treatment in oncology, has a number of limitations associated with undesirable side effects. Metal nanoparticles are very effective in cancer therapy, providing specific selectivity in influencing cells and being a means of drug delivery. Conjugation of chemotherapeutic agents with metal nanoparticles can provide significant benefits in cancer therapy.1 The method of metal-vapor synthesis (MVS) was used to create targeted drug delivery systems based on mono- and bimetallic nanoparticles Au, Fe and AuFe, as well as their conjugates with methotrexate. In the case of MVS of Fe nanoparticles, the use of toluene as an organic reagent led to a partial reduction of iron to FeO, and acetone to oxidation to Fe3+. During the interaction of AuFe bimetal nanoparticles obtained in toluene with methotrexate, the Au0 states are recorded. In the conjugate of methotrexate with AuFe obtained in acetone, the presence of Au+ and Au3+ states is observed. The study of antibacterial activity showed moderate inhibitory activity of conjugates against gram-negative and gram-positive bacteria. Monometallic conjugates exhibit cancer-specific cytotoxicity by affecting the functionality of lysosomes in lung cancer cells. Bimetal conjugates in low concentrations have a high inhibitory potential for lung adenocarcinoma, cervical and colorectal adenocarcinoma cells, and their use has virtually no effect on normal fibroblasts.